Liminatus Pharma, Inc. Class A Common Stock

LIMN · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$2$0-$0-$1
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$0
Change in WC$7-$7$0-$0
Other Non-Cash-$6-$2$0$0
Operating Cash Flow-$1-$9$0-$1
Investing Activities
PP&E Inv.-$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$1-$1$0-$0
Inv. Sales/Matur.$0$0$0$2
Other Inv. Act.-$1$0$0-$2
Investing Cash Flow-$0-$1$0-$0
Financing Activities
Debt Repay.$0$3$0$1
Stock Issued-$3$11$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$3-$3$0$0
Financing Cash Flow$0$11$0$1
Forex Effect$0$0$0$1
Net Chg. in Cash-$1$1$0$0
Supplemental Information
Beg. Cash$1$0$0$0
End Cash$1$1$0$1
Free Cash Flow-$1-$9$0-$1
Liminatus Pharma, Inc. Class A Common Stock (LIMN) Financial Statements & Key Stats | AlphaPilot